News
OCGN
1.320
-5.04%
-0.070
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
Ocugen, Inc. Is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines. Arun Upadhyay, PhD, will speak at the Retina World Congress being held May 9-12, 2024 in Florida.
Barchart · 1d ago
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
Glancy Prongay & Murray LLP has commenced an investigation on behalf of Ocugen, Inc. Investors concerning the Company’s possible violations of the federal securities laws. On April 1, 2024, Oc Eugen disclosed that it had identified certain accounting errors. The Company's stock price fell 10.4% on the news.
Barchart · 3d ago
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Clever Leaves Holdings Inc. Shares dipped 60% to $1.6498 on Monday. The company announced it will voluntarily delist its common shares from the Nasdaq. Shares of Deciphera Pharmaceuticals, Inc. Climbed 73% in today's mid-day session.
Benzinga · 3d ago
Ocugen Inc Lawsuits Dismissed by Pennsylvania Court
TipRanks · 3d ago
OCUGEN ANNOUNCES OCU400—MODIFIER GENE THERAPY—PHASE 1/2 DATA PRESENTATION AT RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT 2024
Reuters · 3d ago
Weekly Report: what happened at OCGN last week (0422-0426)?
Weekly Report · 3d ago
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 6d ago
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Susquehanna raised the price target for Occidental Petroleum Corporation from $70 to $81 on Friday. Chardan Capital increased Ocugen, Inc. Price target from $4 to $5. Keybanc boosted the price targets for Alphabet Inc. And ConocoPhillips.
Benzinga · 04/22 12:32
Key Takeaways From Ocugen Analyst Ratings
4 analysts have expressed a variety of opinions on Ocugen (NASDAQ:OCGN) over the past quarter. The company has an average price target of $6.5 and a 12-month revenue growth rate of 142.6%. The company is developing a gene therapy platform to treat retinal diseases. Oc Eugen Inc is a company focused on discovering and developing novel gene and cell therapies.
Benzinga · 04/22 12:01
Ocugen Is Maintained at Buy by Chardan Capital
Dow Jones · 04/22 11:56
Ocugen Price Target Raised to $5.00/Share From $4.00 by Chardan Capital
Dow Jones · 04/22 11:56
Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $5
Benzinga · 04/22 11:47
Weekly Report: what happened at OCGN last week (0415-0419)?
Weekly Report · 04/22 10:28
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
Seeking Alpha · 04/19 21:05
Ocugen Says It Has Completed Dosing of Subjects With Geographic Atrophy In Cohort 2 Of Phase 1/2 ArMaDa Clinical Trial Of OCU410—A Modifier Gene Therapy
OCU410 is a gene therapy candidate being developed for geographic atrophy. GA is an advanced stage of dry age-related macular degeneration. GA affects approximately 1 million people in the United States. Company says dosing is complete in the second cohort of its Phase 1/2 clinical trial for OCU410.
Benzinga · 04/19 11:15
OCUGEN ANNOUNCES DOSING COMPLETION OF SUBJECTS WITH GEOGRAPHIC ATROPHY IN COHORT 2 OF PHASE 1/2 ARMADA CLINICAL TRIAL OF OCU410—A MODIFIER GENE THERAPY
Reuters · 04/19 11:13
Ocugen stock jumps after $175M securities filing
Seeking Alpha · 04/18 10:21
OCUGEN INC FILES FOR MIXED SHELF OF UP TO $175 MLN - SEC FILING
Reuters · 04/18 10:02
OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023
Ocugen reported earnings per share of -4 cents for the fourth quarter of 2023. The company reported revenue of $6.04 million. Ocugen's results were above the analyst estimate for EPS of -6 cents. The stock was down 1.7% after the market closed.
Investorplace · 04/17 02:53
OCUGEN, INC. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023
Press release · 04/16 22:35
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.